Jason Gerberry
Stock Analyst at B of A Securities
(3.72)
# 700
Out of 4,759 analysts
160
Total ratings
54.39%
Success rate
4.88%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $23 → $20 | $15.36 | +30.21% | 13 | Mar 6, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $9.65 | +3.63% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $122.17 | +36.69% | 5 | Feb 11, 2025 | |
| IMVT Immunovant | Maintains: Buy | $48 → $45 | $20.02 | +124.78% | 4 | Jan 15, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $21.96 | +36.61% | 2 | Jan 9, 2025 | |
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $38.58 | +1.09% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $4.00 | +150.00% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $70.74 | +41.36% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $29.86 | +107.64% | 1 | Sep 24, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $20 → $24 | $3.46 | +593.64% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $1.05 | +185.71% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $140 | $71.18 | +96.68% | 8 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $33.81 | +101.12% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $18.84 | +6.16% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $91 | $131.24 | -30.66% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $26.58 | +16.63% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.19 | +5,620.23% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $34.35 | -15.57% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $16.97 | +118.03% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $36.50 | +53.42% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $33.67 | -10.90% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $28.81 | +118.67% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $138.81 | +56.33% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.37 | +439.37% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $869.58 | -42.50% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $72 → $48 | $4.92 | +875.61% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.18 | +312.84% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $15.44 | +61.92% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.67 | +199.40% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.15 | +277.62% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.04 | +1,823.08% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.61 | +1,544.74% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $214.29 | -55.67% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $61.09 | -1.78% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $26.73 | +38.42% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $94.65 | -4.91% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
Mar 6, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $15.36
Upside: +30.21%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $9.65
Upside: +3.63%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $122.17
Upside: +36.69%
Immunovant
Jan 15, 2025
Maintains: Buy
Price Target: $48 → $45
Current: $20.02
Upside: +124.78%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $21.96
Upside: +36.61%
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $38.58
Upside: +1.09%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $4.00
Upside: +150.00%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $70.74
Upside: +41.36%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $29.86
Upside: +107.64%
Relay Therapeutics
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $3.46
Upside: +593.64%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.05
Upside: +185.71%
Sep 4, 2024
Maintains: Buy
Price Target: $101 → $140
Current: $71.18
Upside: +96.68%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $33.81
Upside: +101.12%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $18.84
Upside: +6.16%
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $131.24
Upside: -30.66%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $26.58
Upside: +16.63%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.19
Upside: +5,620.23%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $34.35
Upside: -15.57%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $16.97
Upside: +118.03%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $36.50
Upside: +53.42%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $33.67
Upside: -10.90%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $28.81
Upside: +118.67%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $138.81
Upside: +56.33%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.37
Upside: +439.37%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $869.58
Upside: -42.50%
May 16, 2023
Maintains: Underperform
Price Target: $72 → $48
Current: $4.92
Upside: +875.61%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.18
Upside: +312.84%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $15.44
Upside: +61.92%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.67
Upside: +199.40%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.15
Upside: +277.62%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.04
Upside: +1,823.08%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.61
Upside: +1,544.74%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $214.29
Upside: -55.67%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $61.09
Upside: -1.78%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $26.73
Upside: +38.42%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $94.65
Upside: -4.91%